ClinicalTrials.gg
CompletedNCT06221475Updated Jun 28, 2024

A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants

A Phase 1 interventional study of BAY2927088 coated tablet 10 mg and [14C]-BAY2927088 solution for infusion in Advanced Non-small Cell Lung Cancer, EGFR Mutation and HER2 Mutation, sponsored by Bayer. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-28.

Sponsored by Bayer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Carcinoma, Non-Small-Cell Lung by Bayer — 3 open to participants now, 5 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · Bayer.

Enrollment
26th of 28
8 · median 85
Started
2024
with 5 others
Phase 1
15 of 28
none open now
Registered
22nd of 28
by date

Among the 28 studies in Carcinoma, Non-Small-Cell Lung by Bayer, this one is the 26th largest by enrollment, is one of 6 that started in 2024, is one of 15 in phase 1, and was the 22nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 28 studies in Carcinoma, Non-Small-Cell Lung by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Carcinoma, Non-Small-Cell Lung by Bayer, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat men who have advanced non-small cell lung cancer (NSCLC). NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body.

Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are proteins that help cells to grow and divide. A damage (also called mutation) to the building plans (genes) for these proteins in cancer cells leads to a production of abnormal EGFR and/or HER2. These abnormal proteins drive the growth and the spread of the cancer. Several EGFR and/or HER2 mutations exist in the cancer cells. The study treatment works by blocking the mutated EGFR and HER2 protein present in NSCLC cells and may help stop the further spread of NSCLC.

BAY2927088 is under development, once it is approved, it may help treat people with NSCLC.

The participants of this study will be healthy men and will have no benefit from the administration of BAY2927088. However, the study will provide important information for the design of subsequent studies with BAY2927088 in people with NSCLC.

The participants in this study will get the non-radiolabeled and radio-labeled study treatment BAY2927088 in the form of tablets and solution by mouth and as an intravenous infusion in the arm. By radiolabeling the study treatment, researchers can track its movement and breakdown in the body of the participants. During the study, the study team will do physical examinations, take medical history, ask the participants questions about their smoking or alcohol consumption habits and other medications used, check vital signs such as blood pressure, heart rate, body temperature and the number of breaths taken per minute (respiratory rate), take blood and urine samples, do HIV (human immunodeficiency virus), hepatitis and optional COVID-19 tests per local regulations, and examine heart health using electrocardiogram (ECG).

Each study participant will go through a first test phase (screening) of up to 28 days before the start of treatment. The study will have two parts. In part 1, the study participants will take a single dose of the non-radiolabeled study treatment in the form of tablets by mouth 30 minutes following a light meal. They will then receive the radiolabeled study treatment as an intravenous infusion in the arm over 15 minutes. After 2 days of washout, the same group of participants will move on to Part 2 of the study. They will take a single dose of the radio-labeled study treatment as a solution by mouth 30 minutes after a light meal. The participants and the study team know what treatment the participants will take. The total duration of the study will be approximately 8 weeks per participant, including an in house stay of approximately 23 days and 22 nights. There will be a final examination on the last day of their in-house stay before the participants are discharged and go home.

The study doctors and their team will contact the participant to learn about the participant's health until the participant completes the study.

03

Conditions studied

  • Advanced Non-small Cell Lung Cancer
  • EGFR Mutation
  • HER2 Mutation
  • Healthy Volunteers

Keywords

  • NSCLC
  • TKI
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed
  • Participant must be 18 or age of legal maturity to 55 years of age inclusive, at the time of signing the informed consent
  • Participants who are overtly healthy as determined by the investigator or medically qualified designee based on medical evaluation including medical history, laboratory tests, physical, cardiac, and neurologic examination
  • (BMI) within the range [18 - 30] kg/m\^2 (inclusive), with bodyweight above/equal to 50 kg
  • Male
  • Study participants of must agree to use adequate when sexually active during the study period and for at least 3 months after the last dose of study intervention, and refrain from donating sperm during this period
  • Participant must have venous access sufficient to allow blood sampling as required by the protocol
  • Participant must be willing to undergo multiple blood draws as required by the protocol
  • Participant must be willing to comply with dietary and fluid requirements during the treatment period (including abstaining from alcohol use)
  • Ability to understand and follow study-related instructions

Exclusion criteria

Exclusion Criteria:

  • Existing relevant diseases of vital organs (e.g., liver diseases, heart diseases, gastrointestinal diseases, interstitial lung disease), central nervous system (for example seizures) or other organs (e.g., diabetes mellitus)
  • Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination, and effects of the study intervention will not be normal
  • Any relevant diseases within 4 weeks prior to the first study intervention administration as judged by the investigator
  • A medical history of risk factors for Torsades de pointes (e.g., family history of long syndrome) or other arrhythmias as judged by the investigator
  • Known history of (or known allergic reaction) to BAY2927088-related compounds, or any components of the formulation
  • History of known or suspected malignant tumors
  • Participants with any type of psychiatric disorder, especially any mood disorders including medical history with suicidal ideation and/or suicide attempts, which may disable the participant to consent
  • Any condition which may result in longer than usual retention of urine or feces in the body, such as pronounced (less than one defecation in 3 days) constipation or symptomatic prostatic hypertrophy
  • Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays of thorax and bony skeleton [excluding spinal column]), during work or during participation in a clinical study in the period of 1 year prior to screening
  • Participant will be excluded when he participated in another study with a radiation burden of 0.1 - 1 mSv (inclusive) in the period of 1 year prior to screening; 1.1 - 2 mSv (inclusive) in the period of 2 years prior to screening; 2.1 - 3 mSv (inclusive) in the period of 3 years prior to screening, etc. (add 1 year per 1 mSv)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Healthy male participants from Netherlands

    In Part 1, participants will receive a single dose of 40 mg of BAY2927088 as oral tablets on Study Day 1 approximately 30 min after a light meal, they will then receive a single dose of a microtracer not exceeding 100 ug of \[14C\]-BAY2927088 and 37 kilo becquerel (kBq) \[1000 nano Curie (nCi)\] of 14C will be administered intravenously (IV) as a 15 min infusion ending at the expected median time to maximum concentration (tmax) for the tablet (2 hours oral post-dose). After 2 days of washout, participants will move on to Part 2. In Part 2, on Study Day 1 approximately 30 min after a light meal, all enrolled participants will receive a single dose of 40 mg BAY2927088 containing approximately 3.7 MBq (100 µCi) \[14C\]-BAY 2927088 administered as an oral solution

    Drug: BAY2927088 coated tablet 10 mg · Drug: [14C]-BAY2927088 solution for infusion · Drug: [14C]-BAY2927088 oral solution

Interventions

06

What researchers measure

Primary outcomes

  1. For Part 1: Absolute bioavailability (F) as percent F (%F) after oral administration as oral to IV ratio of AUC/D (Area under the concentration curve per dose)

    Time frame: Day 1 of Part 1 pre-dose and at multiple time points (up to 3 days) post-dose

  2. For Part 1: AUC of BAY2927088 and [14C]-BAY2927088

    Time frame: Day 1 of Part 1 pre-dose and at multiple time points (up to 3 days) post-dose

  3. For Part 1: AUC/D of BAY2927088 and [14C]-BAY2927088

    Time frame: Day 1 of Part 1 pre-dose and at multiple time points (up to 3 days) post-dose

  4. For Part 1: Cmax (maximum concentration) of BAY2927088 and [14C]-BAY2927088

    Time frame: Day 1 of Part 1 pre-dose and at multiple time points (up to 3 days) post-dose

  5. For Part 1: Cmax/D of BAY2927088 and [14C]-BAY2927088

    Time frame: Day 1 of Part 1 pre-dose and at multiple time points (up to 3 days) post-dose

  6. For Part 2: Amount of BAY2927088 and its metabolites excreted in urine (%AEur), in feces (%AEfec), and in vomit as a percent of the dose (%AEvom, if applicable)

    Based on radioactivity excreted in urine and feces, and vomit as a percentage of the dose to assess mass balance of total radioactivity

    Time frame: Day 1 of Part 2 pre-dose and at multiple time points (minimum up to 6 days, maximum up to 6 weeks) post-dose

  7. For Part 2: AUC of total radioactivity in plasma and whole blood. (AUC(0-tlast) will be used as primary parameter if mean AUC(tlast-∞) >20% of AUC)

    Time frame: Day 1 of Part 2 pre-dose and at multiple time points (minimum up to 6 days, maximum up to 6 weeks) post-dose

  8. For Part 2: Cmax of total radioactivity in plasma and whole blood

    Time frame: Day 1 of Part 2 pre-dose and at multiple time points (minimum up to 6 days, maximum up to 6 weeks) post-dose

  9. For Part 2: AUC of BAY2927088 in plasma. (AUC[0-tlast] will be used as primary parameter if mean AUC[tlast-∞] >20% of AUC)

    Time frame: Day 1 of Part 2 pre-dose and at multiple time points (minimum up to 6 days, maximum up to 6 weeks) post-dose

  10. For Part 2: Cmax of BAY2927088 in plasma

    Time frame: Day 1 of Part 2 pre-dose and at multiple time points (minimum up to 6 days, maximum up to 6 weeks) post-dose

Secondary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAE) and severity of treatment-emergent adverse events

    Time frame: From dosing up to 15 days after last dosing

07

Study locations

1 site
  • ICON plc
    Groningen, 9728NZ, Netherlands
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Apr 2024, 2 months.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 2 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2024
First posted
Jan 24, 2024
StartActual
Jan 25, 2024
Primary completionActual
Apr 5, 2024
CompletionActual
May 8, 2024
Last update
Jun 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06221475
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 24, 2024
Start date
Jan 25, 2024
Primary completion
Apr 5, 2024
Completion
May 8, 2024
Last update
Jun 28, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sevabertinib

Start the discussion